February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  
Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer
Feb 1, 2025, 08:25

Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer

Tian Zhang, Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, shared an article on X she and her colleagues authored:

“Check out our latest paper on circulating immune biomarkers for metastatic kidney cancer! While immunotherapy combos have improved outcomes in RCC, predictive biomarkers for ICI response and resistance are elusive. We attempt to find circulating biomarkers for ICIs.

We prospectively banked plasma and PBMCs from 33 patients with RCC treated with ICIs and evaluated plasma cytokines and circulating cellular subsets. 23 had ipi/nivo as first-line treatment and 9 nivo alone; 1 patient had cabo/nivo. 22 had stable/progressing dz and 11 had responses.

Tian Zhang

Interestingly, higher circulating monocytes esp the CD14+/CD16- subset were seen in patients with ICI responses. These are the white blood cells in circulation that set up shop in the tumor as macrophages.

Tian Zhang

In addition, baseline cytokines IL12/IL23, MIP-1a, MIP-1b, ICAM-1, VCAM-1, IL-8, and TNFa were higher in patients with ICI responses. MIP-1a and MIP-1b interesting as these are macrophage chemokines.

Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer

Changes in TARC, placental growth factor, and VEGF also changed on treatment. While these are not common cytokines to obtain during kidney cancer treatment, they are hypothesis generating for future analyses.

Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer

Notably, we had an exceptional responder who had an amazing response to ipi/nivo – one of our 1st patients on standard ipi/nivo – who had high levels of these 7 cytokines. Perhaps we can find more patients like him!!

Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer

Thanks Joyce Hwang, a current fellow at Duke Cancer Institute, Andy Nixon, Eda Holl, and biostats Yuan Wu for the perseverance over the years — several rejections and many revisions to final pub. Hopefully we will have other larger series of patients that validates this early work!

Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer

Read more details at JCI Insight!”

Circulating immune biomarkers correlating with response in patients with metastatic renal cell carcinoma on immunotherapy

Authors: Joyce K. Hwang et al.

Tian Zhang: Our latest paper on circulating immune biomarkers for metastatic kidney cancer